EKF Diagnostics Holdings (EKF) Fair Value & Analysis
Healthcare · GB · Market cap 115M GBX
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 6 days ago
Share price +0.9% over the past month.
Price vs Fair Value (12 months)
12‑month range £0.2099 – £0.3072 · fair‑value band £0.1800 – £0.3000 · the £0.2600 price screens above the £0.2400 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
EKF Diagnostics Holdings (EKF) currently trades at £0.2600, while our model-based Fair Value estimate is £0.2400 — implying the stock looks roughly 7.7% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, EKF Diagnostics Holdings generated revenue of £51.6M at a net margin of 4.1%. Revenue grew 5.4% year over year. It earns a return on equity of 3.5%. The balance sheet holds a net cash position of £14.4M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test HbA1c, fully automated hemoglobin A1c analyzer for the monitoring and management of diabetes; and STAT-Site W Beta-Hydroxybutyrate analyzer. In addition, the company offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; Lactate Scout Vet, a handheld lactate analyzer for veterinary care; Hemo Vet, a point-of-care hemoglobin and hematocrit analyzer; Lacta…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
EKF Diagnostics Holdings reported revenue of £51.6M in FY2025 versus £81.8M in FY2021, a compound −10.9%/yr. Reported net income was £2.1M in FY2025, compounding −39.5%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABTT34 | R$38.22 | R$30.39 | -20% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is EKF Diagnostics Holdings (EKF) undervalued?
What is the fair value of EKF?
What is the quality score of EKF?
What is the revenue of EKF Diagnostics Holdings (EKF)?
What is the net profit margin of EKF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.